INSY had another bear raid Thursday and ended the day with a hammer. It bounced off 9DMA nicely and should resume its up trend next week. Insys Therapeutics had two designations in the past week and another product in phase 2/3 study. Insider buying since May. Huge institution holding and 52.32% short interest out of a very small float.